Skip to main content

Strand and Pharmidex to Co-Promote, Co-Develop BBB Research Tools

NEW YORK, Feb. 21 (GenomeWeb News) - Strand Life Sciences and Pharmidex have entered into a co-marketing and -product development agreement, the companies said today.


Under the terms of the agreement, Strand and Pharmidex will promote each other's existing products and jointly develop new software to predict the ability of compounds to cross the blood-brain barrier, the companies said.


Strand will primarily provide in silico expertise, while Pharmidex will contribute its expertise in blood-brain barrier research, including in vitro, ex vivo, and in vivo methods.


Financial terms of the agreement were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.